Regen BioPharma, Inc.
RGBP
$0.0548
$0.00479.38%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 43.67% | -10.35% | 35.02% | 35.58% | 18.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.68% | -33.77% | 22.95% | 15.81% | 16.10% |
| Operating Income | -12.07% | 50.00% | -46.19% | -26.76% | -28.30% |
| Income Before Tax | 84.16% | -255.69% | 18.49% | -31.15% | -122.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.16% | -255.69% | 18.49% | -31.15% | -122.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.16% | -255.69% | 18.49% | -31.15% | -122.73% |
| EBIT | -12.07% | 50.00% | -46.19% | -26.76% | -28.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 96.98% | -211.17% | 15.56% | 5.44% | -79.52% |
| Normalized Basic EPS | 96.77% | -211.11% | 27.38% | -5.43% | -78.85% |
| EPS Diluted | 96.98% | -211.17% | 15.56% | 5.44% | -79.52% |
| Normalized Diluted EPS | 96.77% | -211.11% | 27.38% | -5.43% | -78.85% |
| Average Basic Shares Outstanding | 424.41% | 14.30% | 11.89% | 24.61% | 24.07% |
| Average Diluted Shares Outstanding | 424.41% | 14.30% | 11.89% | 24.61% | 24.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |